Jeffrey Kindler’s Centrexion spells out positive data for its PhIII-ready pain drug
The research team at Centrexion Therapeutics, a Boston-based biotech startup led by ex-Pfizer CEO Jeffrey Kindler, turned up at a scientific conference in Europe to spell out their Phase IIb data for a new pain drug the company is developing for osteoarthritis.
Their lead drug is CNTX-4975, which targets the TRPV1 receptor and is aimed at deactivating pain fibers that send pain signals from the knee straight to the brain. That way a single shot should work for six months out, until the fibers regenerate to start flashing those signals again.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.